Irritable Bowel Syndrome (IBS) is one of the leading causes of chronic pain both world-wide and in Australia for which there is a lack of treatments. Chronic pain arises from nerve fibres in the colon wall, which fail to 'reset' back to normal following inflammation. Targeting these nerve endings with drugs is a key advance in IBS treatment. This project will identify selective oxytocin analogues that act in the colon to lower pain in sensory nerves thus providing efficacious pain relief in IBS.
Neuropathic pain is particularly difficult to treat and existing medications have considerable side effects. This project will develop a new set of glycine transport inhibitors that have the potential to provide pain relief without side effects.
Molecular Targets Of Amino Acid/neurotransmitter Conjugates Of Fatty Acids
Funder
National Health and Medical Research Council
Funding Amount
$846,390.00
Summary
This project investigates endogenous chemicals that affect cells important for detecting and responding to pain. We aim to discover how these compounds affect proteins important for nerve cell function, particularly proteins that have a prominent role in detecting and transmitting painful events. The compounds we examine are not themselves likely to be drugs, but future therapies may involve manipulating the levels of these chemicals in the body, or using drugs that mimic the activity of these c ....This project investigates endogenous chemicals that affect cells important for detecting and responding to pain. We aim to discover how these compounds affect proteins important for nerve cell function, particularly proteins that have a prominent role in detecting and transmitting painful events. The compounds we examine are not themselves likely to be drugs, but future therapies may involve manipulating the levels of these chemicals in the body, or using drugs that mimic the activity of these compounds.Read moreRead less
Glycine Transport Inhibitors For The Treatment Of Pain
Funder
National Health and Medical Research Council
Funding Amount
$923,660.00
Summary
Chronic pain is particularly difficult to treat. Whilst currently used opioid drugs are effective in acute pain, they are either ineffective in chronic pain or have considerable side effects. In this project we will develop a new class of analgesics that have a different mechanism of action to traditional analgesics. It is hoped that these new drugs will provide long term pain relief without debilitating side effects.
Novel Analgesic Approaches: Harnessing Functional Interactions Between Sodium Channels And Opioids
Funder
National Health and Medical Research Council
Funding Amount
$329,076.00
Summary
Chronic pain is a debilitating condition that affects the life of one five Australians and has significant socioeconomic impact. Currently available pain killers often do not work, or have intolerable side effects. We have discovered that combination treatment with opioids and a novel venom-derived compound discovered by us provides effective pain relief. The aim of this project is to understand the mechanisms underlying this synergistic effect to develop new treatment approaches for pain.
Identifying Novel Molecular Targets For Treating Chronic Pain.
Funder
National Health and Medical Research Council
Funding Amount
$402,952.00
Summary
Chronic pain is very common, with one in five Australians suffering long-term pain that is serious enough to cause disability. It is extraordinarily difficult to treat. Medicines used to treat normal pain symptoms are usually ineffective on chronic pain patients because the cause of the pain is different. The aim of this project is to identify new drug targets in the spinal cord that are specific for chronic pain so we can develop new medicines to reverse the symptoms safely and effectively.
The Importance Of Receptor Trafficking For Signalling Of Pain And Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$787,604.00
Summary
Inflammation and pain are normal processes that are essential for survival: inflammation fights infections and pain allows avoidance of danger. These processes are normally tightly controlled and are transient. During disease, they become dysregulated and chronic. By understanding the normal processes of inflammation and pain, and by determining how dysregulation causes disease, we aim to develop new treatments for diseases that are a major cause of human suffering.
Silencing Visceral Nociceptors By Targeting NaV1.1: A Novel Therapeutic Approach For Treating Irritable Bowel Syndrome
Funder
National Health and Medical Research Council
Funding Amount
$696,809.00
Summary
Patients with Irritable Bowel Syndrome suffer from chronic abdominal pain and co-morbidities such as over-active bladder. These symptoms arise from sensory nerve fibres in the colon and bladder that signal pain to innocuous stimuli. We are excited to report that a specific voltage-gated sodium channel, called NaV1.1, plays a key pathological role in generating these symptoms. Here, we will specifically target and block NaV1.1 expressing pain-sensing neurons, provide key advances for therapies.
The Role Of Sodium Channels In Pain And Cold Allodynia
Funder
National Health and Medical Research Council
Funding Amount
$349,306.00
Summary
Many types of chronic pain remain poorly treated and severely impact the quality of life of millions of Australians. Cold allodynia in particular, which occurs in several painful human conditions and leads to severe pain from simply touching a cool surface or item, is poorly understood and thus difficult to treat. The aim of this project is to determine the pharmacological mechanism of cold allodynia to develop novel treatment approaches.
A Pharmacological Approach To Define The Contribution Of Nav1.7 To Pain Pathways
Funder
National Health and Medical Research Council
Funding Amount
$501,467.00
Summary
Chronic pain is a debilitating condition that affects the life of one in five Australians and has significant socioeconomic impact. Currently available pain killers often do not work, or have intolerable side effects. We have discovered the most selective blocker for a specific type of sodium channel that is a known pain target and will use this novel molecule to gain insight into the mechanisms of pain and to develop new pain killers.